J&J partners with CSIR-IMTECH on TB treatments

“The Indian subsidiary of US healthcare giant Johnson & Johnson (NYSE: JNJ) announced a new partnership with the Institute of Microbial Technology (IMTECH), part of the Council of Scientific and Industrial Research (CSIR), to unlock the potential of Indian science and help accelerate the discovery of innovative new tuberculosis (TB) treatments.

Under the Memorandum of Understanding, scientists from J&J’s global public health team will work closely with scientists from CSIR-IMTECH, based in Chandigarh, India, on a research and development program to explore potentially more effective, safer, all-oral treatment regimens to tackle multidrug-resistant TB (MDR-TB), as well as new molecular entities to treat all TB patients.

The new research program will capitalize on the CSIR-IMTECH’s world-class expertise in microbial technology and research and the proven research and development capabilities of J&J’s Janssen Pharmaceutical Companies to strengthen the collective potential of our research efforts.”

Read the Pharma Letter here.